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ABSTRACT
Objective: Investigate the possible association of insertion/deletion (2G/G) polymorphism at nucleotide -1607 of the MMP-
1 promoter with the development and progression of renal cancer.
Materials and Methods: In this study, we genotyped 217 individuals, 99 patients with renal cell carcinoma (RCC) and 118
controls without cancer. DNA specimens were extracted from epithelial buccal cells and paraffin-embedded tissue of RCC
patients and from epithelial buccal cells and blood cells of healthy controls.
Results: The difference in frequency of 2G/2G genotype between controls (22.9%) and RCC patients (28.6%) was not
statistically significant (p = 0.461). We also did not find correlation between 2G/2G and histological type of RCC. The
comparison of genotype distribution and frequency of 2G allele in different populations showed a strong variability of 2G
allele frequency among the different ethnic groups. This fact may influence on the collaboration of this 2G allele in RCC or
others diseases.
Conclusion: Our data suggest that the matrix metalloproteinase-1 (MMP-1) promoter polymorphism may not play a signifi-
cant role in renal cell carcinoma patients in Brazil.
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INTRODUCTION
The development of cancer is a complex,
multistage process during which a normal cell under-
goes genetic changes that result in phenotypic alter-
ations and the acquisition of the ability to invade and
colonize distant sites (1,2). Although many factors are
involved in tumor development, interactionsbetween
neoplastic cells and the surrounding microenvironment
are crucial to each step of tumorigenesis. The MMP
family comprises over 20 enzymes that are associ-
atedwith degradation of the ECM, including the base-
ment membrane, as their name implies (3). Among
the MMPs, matrix metalloproteinase-1 (MMP-1, col-
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lagenase-1), is the most highly expressed interstitial
collagenase degrading fibrillar collagen, the most abun-
dant protein in the human body (4). MMP-1 expres-
sion level is increased in several diseases such as ar-
thritis (5), periodontitis (6) arteriosclerosis (7) and
cancer (8,9).
Recently, an insertion/deletion (2G/G) poly-
morphism was reported at nucleotide -1607 relative
to the transcription site of the MMP-1 gene (9). The
2G polymorphism creates a binding site (5'-GGA-’3)
for the ETS transcription factor, influencing its tran-
scriptional activity (10,11) Promoter containing 2G al-
lele displays a significantly higher transcriptional ac-
tivity than 1G promoters (8).
The 2G allele of the MMP-1 promoter poly-
morphism is relatively common and has a frequency
of a little less than 50% of the general population (12).
Association studies have been done to determine
whether the MMP-1 genotype affects the risk of dif-
ferent types of cancers (5,8,9,11-16).
Renal cell carcinoma accounts for 2 percent
of all cancers. Renal cell carcinoma originates in the
cortex and accounts for 80 to 85 percent of malig-
nant kidney tumors (17). This carcinoma occurs
nearly twice as often in men than in women. Pa-
tients are generally over 40 years old at diagnosis,
and the disease occurs predominantly in the seventh
and eighth decades of life (18). However, small, lo-
calized tumors rarely produce symptoms, and for this
reason, the diagnosis is often delayed until after the
disease is advanced. To improve the prognosis of
this disease it is important to clarify the molecular
mechanism of invasion and metastasis of renal cell
carcinoma.
The aim of this study was to investigate pos-
sible correlations between MMP-1 promoter and re-
nal cell carcinoma (RCC) in a Brazilian group.
MATERIALS AND METHODS
Subject selection - This case-control study
consisted of 99 patients withrenal cell carcinoma (56
men, 43 women mean age 59.97 years) and 118 popu-
lation-derived, age-matched controls (62 men, 56
women; mean age 60.5 years), all being ethnic Bra-
zilian. This study protocol was approved by the insti-
tutional review board. At recruitment, written informed
consent was obtained from each subject.
All of the RCC patients were diagnosed his-
tologically and tumors were staged according to the
1997 TNM classification system (19) and graded ac-
cording to the Fuhrman classification system (20).
Sample acquisition - DNA samples of the
patients were obtained from formalin-fixed paraffin-
embedded tissue (23 patients), epithelial buccal cells
(60 patients) and blood cells (16 patients). Patients
were recruited between 2004 and 2006, at the São
Paulo Hospital and Public Servant Hospital of São
Paulo, Brazil (São Paulo, Brazil), and histopathologi-
cally confirmed as a renal cell carcinoma. All DNA
samples of the control group were extracted from
epithelial buccal cells.
Paraffin-embedded tissue - 10-µm sections
were obtained from paraffin-embedded tissue. The
sections were deparaffinized by immersing twice in
xylene for 2 min, followed by twice 99.5% ethanol
for 2 min, and further two times 70% ethanol. There-
after the samples were digested with 1,000µL 0.1M
Tris-HCl (pH 8.0), 0.5 M NaCl, 0.05 M EDTA, 1%
sodium dodecyl sulfate (SDS), and 1 unit of protein-
ase K at 55oC overnight. Then the samples were
mixed well, and centrifuged at 10,000 X g for 15
min. The DNA was extracted with phenol/chloro-
form (1:1). DNA was precipitated by adding cold
ethanol, centrifuged and resuspended in 50µL water
(21,22).
Epithelial buccal cells - The ephitelial buccal
cells were extracted with 100 ng/mL proteinase K
(Sigma Chemical Co.) at 37oC for 1 hour. DNA was
then purified by sequential phenol/chloroform extrac-
tion and salt/ethanol precipitation. DNA was dissolved
in 70µL TE buffer (10 mm Tris (pH 7.8), 1mm EDTA),
and its concentration was determined by measure-
ments of OD 260 (6).
Statistical analysis - Differences in the geno-
types distribution from those expected by the Hardy-
Weinberg equilibrium and the significance of differ-
ences in the observed frequencies of SNP in both
groups were assessed by χ2 test. We also used the
χ2  test to compare the distribution of genotype and
frequency of G2 allele in different populations. T Stu-
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dent test and Fisher test were employed to evaluate
the homogeneity of control and case populations. For
all tests, the p-values of 0.05 were regarded signifi-
cant.
RESULTS
We studied a total of 217 individuals: 99 renal
cancer patients and 118 non-cancer controls. The
Table 1 – Characteristics of cases and controls.
Male/Female
Age (mean ±  SD)
Smokers (N/%)
Cases
(N =  99)
58/46
60.54± 13.68
30 (28.85%)
Controls
(N = 118)
62/56
59.90 ± 12.50
29 (24.58%)
p Value
0.726 (a)
0.623 (b)
0.345 (a)
a = chi square test, b = student t test.
baseline characteristics of the patients and controls
are summarized in Table-1.
The genotypes of all subjects were clearly
determined by PCR-RFLP. Figure-1 shows the RFLP
pattern after digestion with BGL II and after diges-
tion with Alw I.
Polymorphism distribution in the control and
case population was according to the Hardy-Weinberg
principle (χ2 = 0.00, p = 1.000 and χ2 = 0.04, p = 0.981
respectively).
Figure 1  –  RFLP analyses of MMP-1 promoter polymorphism. ALWI digests the 181 bp 2G amplicon (166 bp + 15 bp), leaving the 1G
amplicon (180 pb) intact. Bgl II digests the 180 pb 1G (153 bp + 27 bp), leaving the 2G amplicon (181 bp) intact. Samples 1 and 3 are 1G/
2G heterozygotes. Samples 2 and 5 are 2G/2G homozygotes. Sample 4 is 1G/1G homozygote.
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Table 3 – Distribution of MMP-1 polymorphism in case and controls.
Genotype N 0%    N  % p Value *
2G/2G 29 028.6 027 22.9
1G/2G 42 048.8 059 50.0   0.461
1G/1G 28 022.6 032 27.1
Total 99 100 118 100
Cases Controls
* = p Value obtained by chi-square test.
We analyzed the correlation between tobacco
smoking and RCC and no association was found (p =
0.345) (Table-1).
In the renal cancer group, allele frequency of
2G was 51%, in comparison with 49.0% in control
group, did not show any significant statistic difference
(p = 0.48). The genotype distribution in RCC patients
and controls are shown in Table-2. The frequency of
the 2G/2G genotype showed in Table-3 in patients
(29.3%) did not significantly differ from the values
for normal controls (22.9%) (p = 0.461). Further, we
Table 2 – Pathological characteristics of 99 RCC patients.
Histological type
TNM stage (a)
Fuhrman grade (b)
Clear cells
Chromophobe
Papillary
transitional cell carcinoma
T1
T2
T3
T4
G1
G2
G3
G4
  N (%)
75 ( 75.8 )
15 (15.1)
07 (7.0)
02 (2.0)
36 (36.4)
20 (20.2)
27 (27.3)
16 (16.2)
09 (9.1)
55 (55.6)
17 (17.2)
03 (3.0)
a = tumor stage according to TNM (20); b = Tumor stage according to the 1997 grading system (19).
analyzed the a possible correlation between patho-
logical data and genotype frequency of MMP-1 poly-
morphism in RCC patients and we also found no cor-
relation (Table-4).
In Table-5 we compared the distribution of
the MMP-1 genotype in our controls with the data
previously reported for other study populations
(9,15,16,23-26). Chi-square analysis indicated signifi-
cant differences in genotype distributions of MMP-
1 -1607 promoter between Brazilians and reported
data on Japanese (p = 0.003 and p < 0.001), Tai-
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Table 4  – Correlation between pathological data and genotype frequency of MMP-1 polymorphism in RCC patients.
Histological type
TNM stage (a)
Fuhrman grade (b)
Clear cells
Chromophobe
Papillary
Transitional cell carcinoma
T1
T2
T3
T4
G1
G2
G3
G4
2G/2G N (%)
  22 (73.4%)
  04 (13.4%)
  02 (6.7%)
  02 (6.7%)
  10 (34.5%)
005 (17.2%)
0 8 (27.6%)
0 6 (20.7%)
0 2 (8.3%)
  15 (62.5%)
0 5 (20.8%)
0 2 (8.3%)
1G/2G N (%)
  29 (70.7%)
0 8 (20%)
0 4 (10%)
0 0 (0.0%)
  14 (33.3%)
  08 (19.1%)
  16 (38.1%)
  04 (9.5%)
  04 (11.1%)
  24 (66.7%)
0 8 (22.2%)
0 0 (0.0%)
1G/1G N (%)
  24 (85.7%)
0 3 (10.7%)
0 1 (3.6%)
0 0 (0.0%)
0 3 (12.5%)
  16 (66.7%)
  04 (16.7%)
  06 (21.4%)
0 3 (12.5%)
  16 (66.7%)
  04 (16.7%)
  01 (4.2%)
 p Value
0.618 (c)
0.273 (d)
0.803 (c)
Genotype
a = tumor stage according to TNM (20); b = tumor stage according to the  1997 grading system (19); c = p Value obtained by Fisher exact
test; d = p Value obtained by chi-square test.
Table 5 – Distribution of genotype and frequency of G2 allele in different populations.
Population
Brazilian (n = 118)
Brazilian (n = 37)
Norwegian (n = 364)
Caucasian US American (n = 451)
Japanese (n = 210)
Japanese (n = 150)
Japanese (n = 140)
Taiwanese (n = 135)
Korean (n = 332)
  1G/1G (%)  1G/2G (%)  2G/2G (%) G2 Allele
0.45
0.49
0.49
0.53
0.65
0.62
0.70
0.66
0.67
    p Value (*)
   0.982
   0.949
   0.260
< 0.001
   0.003
< 0.001
< 0.001
< 0.001
Reference
This study
De Souza et al. 6
Wiencke et al. 23
Young et al. 24
Hirata et al. 9
Nishioka et al. 25
Hashimoto et al. 15
Lai et al. 16
W. Ju et al 26
032 (27.1)
010 (27)
087 (25)
111 (24.61)
025 (11.9)
030 (20.0)
017 (12.1)
017 (13)
033 (9.9)
059 (50.0)
018 (48.7)
197 (52)
196 (43.46)
096 (45.7)
056 (37.3)
048 (34.3)
057 (42)
154 (46.4)
27 (22.9)
09 (24.3)
80 (23)
144 (31.93)
089 (42.4)
064 (42.7)
075 (53.6)
061 (45)
145 (43.7)
Genotypes
* =  p Value obtained by chi-square test.
wanese (p < 0.001) and Koreans (p < 0.001)
(9,15,25). However, there was no difference between
Brazilians, Norwegians and Caucasian US Ameri-
cans (23,24).
COMMENTS
Renal cell carcinoma (RCC) accounts for 3%
of adult human cancers and it is becoming more com-
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mon (27). Major risk factors include cigarette smok-
ing, obesity and hypertension (28). RCC represents
just about 85% of newly diagnosed kidney malignan-
cies, occurring at an estimated rate of 4.4 to 11.1 cases
per 100,000 person-years with a steady rise in the
rates of RCC of 2.3% to 4.3% annually (29). There is
a lack of an effective systemic therapy for RCC, which
is necessary for approximately 30% of initially local-
ized disease and 30% of patients presenting RCC with
metastases identified at the time of diagnosis, with a
1-year survival rate of 26% (30). Renal tumors are
classified as different histopathological subtypes with
diverse clinical behavior and genetic mutations that
are not completely understood.
A better understanding of the tumor gene
activity and its relationships may help on prognosis
prediction and on molecular therapies development.
Proteolytic enzymes play a fundamental role
in cancer progression providing an access for tumor
cells to the vascular and lymphatic systems. Among
all proteolytic enzymes, the MMP family has reached
an outstanding importance due to their ability to cleave
virtually any component of the extracellular matrix
(31). Matrix metalloproteinase-1 is a member of this
family that is expressed by most normal cell types
and there is evidence suggesting that in pathological
conditions like cancers the expression is up regulated
(5,8,9,11-16).
Rutter et al. (10) reported that a common
single nucleotide polymorphism (SNP) in the promoter
of MMP-1 is associated with enhanced transcription
of this gene. A correlation between the transcription-
enhancing insertion of a single G nucleotide in the
MMP-1 promoter has been associated with different
types of tumors (8,9,11,12). In a recent study Hirata
and collaborators reported that distribution of 2G/2G
in RCC patients was statistically different from the
control group in the Japanese population (9).
The present population-based, control-case in
São Paulo, Brazil, did not confirm the relationship be-
tween MMP-1 promoter polymorphism and risk of
renal cell carcinoma. Using a total of 217 individuals,
99 RCC patients and 118 control individuals we found
a lack of association between MMP-1 polymorphism
and renal cell carcinoma. The discrepancy among our
results and the others (8,9,11,12) may be caused by
the relatively small numbers of patients and multi-eth-
nic composition of the Brazilian group.
Comparing the distribution MMP-1 promoter
-1607 genotype in our controls with the data reported
previously for other study populations (Table-5), It is
clear that the 2G variant genotype is associated to
ethnicity. Chi-square analysis showed a significant
difference in the genotype distribution between our
Brazilian group and data reported for Japanese (p ≤
0.001 and p = 0.003), Taiwanese (p ≤ 0.001) and
Korean (p ≤ 0.001) populations (9,25,26). This fact
suggests that this polymorphism may be associated
with ethnicity and shows the importance of the mo-
lecular epidemiological studies in different popula-
tions.
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